Kala Pharmaceuticals Inc (KALA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kala Pharmaceuticals Inc (KALA) has a cash flow conversion efficiency ratio of -0.455x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.88 Million) by net assets ($23.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kala Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Kala Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Kala Pharmaceuticals Inc carry for a breakdown of total debt and financial obligations.
Kala Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kala Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CME Group Bhd
KLSE:7018
|
0.059x |
|
Nobel29 Resources Corp
V:NBLC
|
0.055x |
|
Clean & Carbon Energy S.A.
WAR:CCE
|
-0.044x |
|
Commander Resources Ltd
V:CMD
|
-0.123x |
|
Scisparc Ltd
NASDAQ:SPRC
|
22.975x |
|
CLOCKCHAIN AG INH O.N.
F:U1DA
|
N/A |
|
Fon SE
WAR:FON
|
0.005x |
|
Scout Gaming Group AB
ST:SCOUT
|
-0.665x |
Annual Cash Flow Conversion Efficiency for Kala Pharmaceuticals Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Kala Pharmaceuticals Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Kala Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $12.33 Million | $-29.38 Million | -2.383x | +35.98% |
| 2023-12-31 | $7.50 Million | $-27.93 Million | -3.722x | +10.51% |
| 2022-12-31 | $18.97 Million | $-78.91 Million | -4.159x | +35.43% |
| 2021-12-31 | $16.80 Million | $-108.23 Million | -6.441x | -610.16% |
| 2020-12-31 | $100.00 Million | $-90.69 Million | -0.907x | +70.96% |
| 2019-12-31 | $29.69 Million | $-92.72 Million | -3.123x | -505.76% |
| 2018-12-31 | $104.99 Million | $-54.12 Million | -0.516x | -35.58% |
| 2017-12-31 | $89.68 Million | $-34.10 Million | -0.380x | -222.02% |
| 2016-12-31 | $-87.76 Million | $-27.35 Million | 0.312x | -88.04% |
| 2015-12-31 | $-5.79 Million | $-15.09 Million | 2.605x | +155.31% |
| 2014-12-31 | $3.26 Million | $-15.36 Million | -4.709x | +91.23% |
| 2013-12-31 | $202.00K | $-10.84 Million | -53.673x | -- |
About Kala Pharmaceuticals Inc
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more